Anthropic, the artificial intelligence giant, is entering the pharmaceutical industry and has announced that it will develop its own drugs

Anthropic, one of the most influential companies in the field of artificial intelligence worldwide, has made a surprising announcement that could redefine the pharmaceutical industry: the company plans to begin developing its own drugs, according to a report published by STAT News in late June 2025.

This move represents a significant expansion of Anthropic’s business; the company, founded in 2021, has been known primarily for its large language models and its conversational assistant, Claude. While Anthropic has so far positioned itself as a provider of AI infrastructure and tools for other industries, this new strategic direction transforms it into a direct player in the biotechnology and pharmaceutical sectors.

What This Initiative Entails

Anthropic’s decision to develop its own drugs comes amid growing interest from major tech companies in the healthcare sector and pharmaceutical discoveries. Artificial intelligence has already demonstrated considerable potential in accelerating the process of identifying candidate molecules for new treatments, significantly reducing the time and costs associated with traditional research.

AI companies have the ability to analyze vast amounts of biological, genetic, and chemical data within a timeframe that would be impossible to achieve using traditional laboratory methods. It is precisely this computational power that appears to underpin Anthropic’s plan to become an independent player in the discovery of new active compounds with therapeutic potential.

According to STAT News, Anthropic does not intend to remain merely a technology provider for the pharmaceutical industry; rather, it aims to take control of the entire drug development chain, from identifying biological targets to the early stages of research.

An Industry First

Anthropic is not the first tech company to take an interest in the pharmaceutical sector. Google DeepMind has already made waves in the scientific community with AlphaFold, the tool that revolutionized our understanding of protein structure. For its part, Microsoft has invested heavily in partnerships with biotech companies to accelerate drug discovery through AI. Startups dedicated exclusively to this field, such as Insilico Medicine and Recursion Pharmaceuticals, have already entered clinical trials with molecules identified using artificial intelligence algorithms.

What sets Anthropic’s announcement apart is the company’s scale and reputation for the safety and reliability of its AI systems—essential factors when it comes to applications that directly impact human health.

Why This Matters for Romania

The expansion of major artificial intelligence companies into the pharmaceutical sector has direct implications for Romania as well, both from the perspective of the healthcare system and the research and business environment.

First, if Anthropic and other similar companies succeed in significantly accelerating the drug discovery process, Romania could benefit, in the medium and long term, from faster access to innovative therapies for oncological, neurological, or infectious diseases—areas in which the Romanian healthcare system faces serious challenges.

Second, Romanian universities and research institutes working in the fields of bioinformatics, medicinal chemistry, or molecular biology could find opportunities for collaboration or funding within this global trend, given that technology companies are actively seeking specialized scientific expertise.

Last but not least, the local pharmaceutical industry, represented by manufacturers such as Antibiotice Iași and Terapia Cluj, will need to closely monitor how the adoption of AI in global pharmaceutical research will reshape the international competitive landscape.

Anthropic’s announcement also raises regulatory questions: relevant agencies, including the European Medicines Agency (EMA), will need to adapt the legislative framework to evaluate and approve drugs discovered primarily through automated AI processes.

It remains to be seen how soon Anthropic will present concrete results from this new strategic direction and whether its integrated business model—combining technology with in-house pharmaceutical research—will become an industry standard or remain an isolated experiment.

📰 Main sources:

• STAT News